Results 1 to 10 of about 15 (15)

Long-term follow up of carbohydrate metabolism and adverse events after termination of Omnitrope® treatment in children born small for gestational age

open access: yesTherapeutic Advances in Endocrinology and Metabolism, 2021
Background: Recombinant human growth hormone (rhGH) therapy can affect carbohydrate metabolism and lead to impaired glucose tolerance during treatment.
Mieczyslaw Walczak   +8 more
doaj   +1 more source

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

open access: yesPharmaceuticals, 2021
Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System ...
Manuel García-Goñi   +3 more
doaj   +1 more source

Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope): data from the PATRO Adults study

open access: yesTherapeutic Advances in Endocrinology and Metabolism, 2020
Background: To assess the safety (particularly the occurrence of malignancies) of growth hormone (GH) replacement (Omnitrope ® ) in adults with GH deficiency, using data from the ongoing PATRO Adults post-marketing surveillance study.
Paolo Beck-Peccoz   +6 more
doaj   +1 more source

Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies

open access: yesBMC Endocrine Disorders, 2020
Background In 2007, Omnitrope® was the first biosimilar recombinant human growth hormone (rhGH) to be approved in Sweden for treatment in adults and children. Over 10 years’ safety and effectiveness data for biosimilar rhGH can now be presented.
Elena Lundberg   +4 more
doaj   +1 more source

Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope in children requiring growth hormone treatment

open access: yesTherapeutic Advances in Endocrinology and Metabolism, 2013
Objective: To describe the rationale, design and first data from PATRO Children, a postmarketing surveillance of the long-term efficacy and safety of somatropin (Omnitrope ® ) for the treatment of children requiring growth hormone treatment.
Roland Pfäffle   +7 more
doaj   +1 more source

Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope for the treatment of adult patients with growth hormone deficiency

open access: yesTherapeutic Advances in Endocrinology and Metabolism, 2012
Objective : To describe the rationale and design of PATRO Adults, a postmarketing surveillance study of the long-term efficacy and safety of somatropin (Omnitrope ® ) for the treatment of adult patients with growth hormone deficiency (GHD).
Paolo Beck-Peccoz   +4 more
doaj   +1 more source

Patients’ perceptions on the usability of the SurePal™ self-injection device for Omnitrope: a questionnaire-based observational study conducted in paediatric patients in France

open access: yesTherapeutic Advances in Endocrinology and Metabolism, 2017
Background: A questionnaire-based survey was conducted to evaluate attitudes towards a reusable self-injection system, SurePal™, among paediatric patients with growth disturbances who were prescribed treatment with somatropin (Omnitrope ® ) as part of ...
Régis Coutant   +3 more
doaj   +1 more source

No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study

open access: yesBMC Endocrine Disorders, 2019
Background To evaluate the impact of treatment with recombinant human growth hormone (rhGH; Omnitrope®) on the risk of diabetes mellitus in adults with growth hormone deficiency (GHD), using data from the ongoing PATRO Adults post-marketing surveillance ...
Paolo Beck-Peccoz   +6 more
doaj   +1 more source

Ten years of biosimilar recombinant human growth hormone in Europe

open access: yesDrug Design, Development and Therapy, 2017
Paul Saenger Division of Pediatric Endocrinology, Department of Pediatrics, Winthrop University Hospital, Mineola, NY, USA Abstract: Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years.
Saenger P
doaj  

Growth hormone treatment in children with Prader–Willi syndrome: safety and effectiveness data from the PATRO Children study

open access: yesTherapeutic Advances in Endocrinology and Metabolism
Background: Recombinant human growth hormone (rhGH, somatropin) therapy is approved in children with Prader–Willi syndrome (PWS). Objectives: To report safety and effectiveness data for children with PWS treated with biosimilar rhGH (Omnitrope ® , Sandoz)
Constanze Lämmer   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy